Erratum to: Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma

被引：0
|
作者：
Masashi Niwakawa
Katsuyoshi Hashine
Raizo Yamaguchi
Hirofumi Fujii
Yasuo Hamamoto
Koichi Fukino
Takahiko Tanigawa
Yoshiteru Sumiyoshi
机构：
[1] Division of Urology,Department of Urology
[2] Shizuoka Cancer Center Hospital,Division of Clinical Oncology
[3] National Hospital Organization,Department of Medical Oncology
[4] Shikoku Cancer Center,Department of Urology
[5] Jichi Medical University,undefined
[6] Tochigi Cancer Center Hospital,undefined
[7] Bayer Yakuhin,undefined
[8] Ltd.,undefined
[9] Teikyo University School of Medicine,undefined
来源：
Investigational New Drugs | 2012年 / 30卷 / 3期
关键词：
D O I：
10.1007/s10637-011-9771-9
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1274 / 1275
页数：1
相关论文
共 50 条
  • [31] Phase I Trial of Sunitinib Malate plus Interferon-α for Patients with Metastatic Renal Cell Carcinoma
    Motzer, Robert J.
    Hudes, Gary
    Wilding, George
    Schwartz, Lawrence H.
    Hariharan, Subramanian
    Kempin, Susan
    Fayyad, Rana
    Figlin, Robert A.
    CLINICAL GENITOURINARY CANCER, 2009, 7 (01) : 28 - 33
  • [32] Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: Toxicity and immunological effects
    Hutson, TE
    Molto, L
    Mekhail, T
    Elson, P
    Finke, J
    Tannenbaum, C
    Borden, E
    Dreicer, R
    Olencki, T
    Bukowski, RM
    CLINICAL CANCER RESEARCH, 2003, 9 (04) : 1354 - 1360
  • [33] PHASE-II STUDY OF INTERFERON-ALPHA IN METASTATIC RENAL-CELL CARCINOMA - A PROGRESS REPORT
    QUESADA, JR
    SWANSON, DA
    GUTTERMAN, JU
    JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (08) : 1086 - 1092
  • [34] A PHASE-IA TRIAL OF SEQUENTIAL ADMINISTRATION RECOMBINANT DNA-PRODUCED INTERFERONS - COMBINATION RECOMBINANT INTERFERON-GAMMA AND RECOMBINANT INTERFERON-ALPHA IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA
    ERNSTOFF, MS
    NAIR, S
    BAHNSON, RR
    MIKETIC, LM
    BANNER, B
    GOODING, W
    DAY, R
    WHITESIDE, T
    HAKALA, T
    KIRKWOOD, JM
    JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (10) : 1637 - 1649
  • [35] A Phase I Trial of Weekly Gemcitabine and Subcutaneous Interferon Alpha in Patients with Refractory Renal Cell Carcinoma
    F. Perez-Zincer
    T. Olencki
    G.T. Budd
    D. Peereboom
    P. Elson
    R.M. Bukowski
    Investigational New Drugs, 2002, 20 : 305 - 310
  • [36] A Phase I trial of weekly gemcitabine and subcutaneous interferon alpha in patients with refractory renal cell carcinoma
    Perez-Zincer, F
    Olencki, T
    Budd, GT
    Peereboom, D
    Elson, P
    Bukowski, RM
    INVESTIGATIONAL NEW DRUGS, 2002, 20 (03) : 305 - 310
  • [37] A PHASE-I TRIAL OF RECOMBINANT INTERFERON-ALPHA AND ALPHA-DIFLUOROMETHYLORNITHINE IN METASTATIC MELANOMA
    CROGHAN, MK
    BOOTH, A
    MEYSKENS, FL
    JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS, 1988, 7 (04): : 409 - 415
  • [38] Phase II clinical trial of sorafenib plus interferon-alfa treatment for patients with metastatic renal cell carcinoma in Japan
    Eto, M.
    Wada, Y.
    Hirao, Y.
    Mita, K.
    Arai, Y.
    Kimura, G.
    Shinohara, N.
    Hinotsu, S.
    Tatsugami, K.
    Naito, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S673 - S673
  • [39] Prospective study of combined treatment with interferon-alpha and active vitamin D3 for Japanese patients with metastatic renal cell carcinoma
    Obara, Wataru
    Mizutani, Yoichi
    Oyama, Chikara
    Akaza, Hideyuki
    Ishii, Nobuhisa
    Kohri, Kenjiro
    Namiki, Mikio
    Okuyama, Akihiko
    Shima, Hiroki
    Yokoyama, Masayoshi
    Shuin, Taro
    Miki, Tsuneharu
    Watanabe, Yoshiyuki
    Fujioka, Tomoaki
    INTERNATIONAL JOURNAL OF UROLOGY, 2008, 15 (09) : 794 - 799
  • [40] A phase I study of S-1 in combination with sorafenib in metastatic renal cell carcinoma (mRCC).
    Ozono, Seiichiro
    Takayama, Tatsuya
    Fujisawa, Masato
    Miyake, Hideaki
    Hashine, Katsuyoshi
    Ninomiya, Iku
    Tatsugami, Katsunori
    Sakai, Hideki
    Ohba, Kojiro
    Akaza, Hideyuki
    Tsukamoto, Taiji
    Naito, Seiji
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
12345